Literature DB >> 16757063

Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine.

Pamela Rendi-Wagner1, Michael Kundi, Andrea Mikolasek, Andreas Vécsei, Martin Frühwirth, Herwig Kollaritsch.   

Abstract

BACKGROUND: This study was undertaken to analyse the epidemiology of pertussis disease among hospitalised children during the transition period from whole-cell to acellular pertussis vaccine in order to compare the respective estimates of vaccine effectiveness.
METHODS: Surveillance was conducted between 1 January 1996 and 31 December 2003. The data originated from a voluntary hospital-based surveillance network including all 44 nationwide paediatric departments.
RESULTS: The mean annual hospitalisation incidence for children decreased over time, from 27.9 per 100,000 population in 1996 to 6.8 cases per 100,000 population in 2003. The mean age of reported hospitalised pertussis cases was 4.7 years (+/- 5.5 S.D.), increasing from 4.06 years (+/- 4.6 S.D.) in 1996 to 5.5 years (+/- 8.6 S.D.) in 2003. Estimated vaccine effectiveness (after three vaccine doses) was 79% for the whole-cell versus 92% for the acellular pertussis vaccine. A significantly higher proportion (19%) of fully immunised children among hospitalised patients was observed for the years where only acellular pertussis vaccine was used compared to whole-cell vaccine era (2%) which was, however, mainly due to children above 2 years of age.
CONCLUSIONS: Our results imply that despite high vaccination coverage rate, pertussis is still a considerable cause of hospital admissions in children in Austria where it remains to be shown that the novel vaccination strategy of additional booster doses in adolescents and adults will control disease in the long term.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757063     DOI: 10.1016/j.vaccine.2006.05.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Bordetella pertussis evolution in the (functional) genomics era.

Authors:  Thomas Belcher; Andrew Preston
Journal:  Pathog Dis       Date:  2015-08-21       Impact factor: 3.166

2.  The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible consequences for vaccine development.

Authors:  Andrew Preston
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

Review 3.  Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis.

Authors:  T Roice Fulton; Varun K Phadke; Walter A Orenstein; Alan R Hinman; Wayne D Johnson; Saad B Omer
Journal:  Clin Infect Dis       Date:  2016-02-07       Impact factor: 9.079

4.  The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia.

Authors:  Helen E Quinn; Peter B McIntyre
Journal:  Bull World Health Organ       Date:  2011-07-05       Impact factor: 9.408

Review 5.  Pertussis.

Authors:  Giovanni Gabutti; Chiara Azzari; Paolo Bonanni; Rosa Prato; Alberto E Tozzi; Alessandro Zanetti; Gianvincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

6.  Multiplex real-time PCR assay for detection and differentiation of Bordetella pertussis and Bordetella parapertussis.

Authors:  Valentina Kolodkina; Vladimir Martinov; Andrey Babenko
Journal:  Iran J Microbiol       Date:  2014-06

Review 7.  DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination.

Authors:  Yahiya Y Syed
Journal:  Paediatr Drugs       Date:  2019-10       Impact factor: 3.930

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.